FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to pharmacology and medicine and aims at treating COVID-19 coronavirus infection. For the treatment of COVID-19, a hexapeptide of formula H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH (I) or its pharmaceutically acceptable salt are used.
EFFECT: use of the invention provides effective treatment of the symptoms of COVID-19.
4 cl, 1 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF DALARGIN FOR PRODUCTION OF DRUG PREPARATIONS FOR PREVENTING PNEUMONIA | 2020 |
|
RU2728938C1 |
| MEANS FOR PREVENTION OF INTERSTITIAL PNEUMONIA | 2020 |
|
RU2747550C1 |
| INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6 | 2020 |
|
RU2737799C1 |
| METHOD OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME BY DALARGIN AND A PULMONARY SURFACTANT | 2020 |
|
RU2728821C1 |
| STABLE AQUEOUS PHARMACEUTICAL COMPOSITION FOR INHALATIONS CONTAINING A HEXAPEPTIDE | 2020 |
|
RU2739573C1 |
| AGENT FOR REDUCING RISK AND RELIEVING SYMPTOMS OF BETA-CORONAVIRUS INFECTION | 2021 |
|
RU2747890C1 |
| MEANS AND METHOD FOR PREVENTION OF INTERSTITIAL PNEUMONIA OF INFECTIOUS ETIOLOGY | 2021 |
|
RU2784177C1 |
| METHOD FOR TREATMENT OF LUNG DISEASES BY INHALATION ADMINISTRATION OF MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2770364C1 |
| METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
| ANTI-SARS-COV-2 VIRAL AGENT ANTIPROVIR | 2020 |
|
RU2738885C1 |
